cyrilzakka/clinical-trials huggingface dataset:
Testing the Anesthetic Effectiveness of Three Different Dental Local Anesthetics Injected Next to a Lower First Molar

Infiltration (injecting next to the tooth) injections are common in dentistry and a number of studies have shown that articaine anesthetic, when injected next to the tooth as a supplemental injection, works very well following a typical inferior alveolar (lower jaw) nerve block. No study has compared 4% articaine with 1:100,000 epinephrine, 4% prilocaine with 1:200,000 epinephrine, and 4% lidocaine with 1:100,000 epinephrine in mandibular (lower jaw) infiltration injections of the first molar. The purpose of this prospective, randomized, double-blind, crossover study is to compare the degree of anesthesia obtained from the three solutions as a primary infiltration injection next to the mandibular first molar. The investigators also will record the pain of injection and postoperative pain.

Using a crossover design, 60 adult subjects will receive three injections consisting of a primary mandibular first molar infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine, 1.8 mL of 4% prilocaine with 1:200,000 epinephrine, and 1.8 mL of 4% lidocaine with 1:100,000 epinephrine in three separate appointments spaced at least one week apart. With the crossover design, 180 infiltrations will be given for the first molar and each subject will serve as his or her own control. Ninety infiltrations will be administered on the mandibular left side and ninety administered on the mandibular right side. The order of the three injections will be assigned randomly and the dentist and subject will be blinded about which anesthetic the subject is given. The anesthetics used in this study are not experimental. An electric pulp tester will be used to test the lower back teeth (molars and premolars) for anesthesia in 3-minute time intervals for a total of 60 minutes. The pain of injection and postoperative pain will be recorded in a survey. The data will be statistically analyzed.

Eligibility Criteria:
Inclusion Criteria:

* between the ages of 18 and 65 years.
* in good health (ASA classification II or lower).
* able to provide informed consent.

Exclusion Criteria:

* allergy to articaine, lidocaine or prilocaine.
* history of significant medical problems (ASA classification III or greater).
* depression (taking tri-cyclic antidepressant medications to control).
* have taken CNS depressants (including alcohol or any analgesic medications) within the last 48 hours prior to testing.
* lactating or pregnant.
* inability to give informed consent.
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV. Patients who become infected despite immunization will be studied to see if receiving the vaccine before becoming infected will help keep HIV levels (viral load) low.

Volunteers receive 7 blinded, intramuscular vaccinations (at Months 0, 1, 6, 12, 18, 24, 30) containing either the AIDSVAX B/B vaccine or a placebo (aluminum adjuvant only). Volunteers are randomized in a 2 to 1 vaccine-to-placebo ratio. HIV-uninfected persons are followed for a total of 16 visits beginning at screening and continuing until Month 36. Patients who become HIV infected during study are followed every 4 months for at least 24 months.

Eligibility Criteria:
Exclusion Criteria

You will not be eligible for this study if you:

* Use injection drugs.
* Have a history of any serious diseases or conditions, including lymphoma.
* Have ever received an HIV vaccine.
* Have taken post-exposure treatment to prevent HIV infection within 4 weeks prior to study entry.
* Are planning to take other HIV vaccines during this study.
* Are pregnant.
* Have taken certain medications or received certain therapies, including chemotherapy and radiation.
* Have received certain vaccines within 2-4 weeks prior to study entry.

You may be eligible for this study if you:

* Are HIV-negative.
* Are between 18 and 60 years old.
* Are available for 3 years of follow-up.
* Agree to use effective methods of birth control during the study and for 90 days after.
* Are one of the following:
* A woman who is currently in a sexual relationship with an HIV-positive man.
* A woman who has had more than one male partner and at least one sexually transmitted disease (STD) within the past 12 months.
* A man who has sex with men and has had anal intercourse within the past 12 months. (You will not be eligible if you have been in the same relationship with only one HIV-negative man for at least 12 months.)
Study of Mental Health and Relationships

The goal of this clinical trial is to test effects of the Great Life Mentoring (GLM) program on the mental health and adaptive functioning on school-age youth (ages 9-16) from low-income families who are receiving outpatient mental health services. The main questions it aims to answer are:

• Does participation in the GLM program improve mental health and related outcomes among school-age youth (9- to 16-years-old) from low-income families as an adjunct to outpatient mental health services? 180 youth will be enrolled in the study and assigned randomly to either continue mental health services as usual (SAU) or to continue mental health services while also participating in GLM (SAU+GLM). Participating youth, and their parent/guardians and therapists, will be surveyed annually. Mental health services records also will be obtained with appropriate permissions. . Researchers will compare the SAU and SAU+GLM groups to see if participation in GLM has an effect on the mental health and related outcomes of study youth.


Eligibility Criteria:
Inclusion Criteria:

* Youth is between 9- and 16-years-old
* Youth meets eligibility criteria for the Great Life Mentoring program, which include receiving publically-subsidized outpatient mental health care

Exclusion Criteria:

* Parental primary language other than English
* Youth difficulties in cognitive functioning that would preclude ability to complete study assessments
Investigation of Cisplatin-Related Kidney Toxicity

The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin.

This study will also collect DNA for future analysis.

This study will look for novel biomarkers of kidney injury in patients receiving cisplatin in patients currently receiving cisplatin.

DNA will be collected both prospectively and retrospectively (from patients that have previously received cisplatin.

Eligibility Criteria:
Prospective Analysis Group

Inclusion Criteria:

* Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy.
* Aged 18 years and older.
* Ability to understand and willingness to sign a written consent document.
* Patients may be receiving cisplatin in combination with other chemotherapeutic agents.
* Patients may be receiving cisplatin in the context of another clinical trial.

Exclusion Criteria:

* Prior receipt of cisplatin.
* Patients on dialysis or other renal replacement therapy prior to starting cisplatin.
* Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible).

Retrospective Analysis Group

Inclusion Criteria:

* Patients that have previously received intravenous cisplatin as part of cancer chemotherapy.
* Aged 18 years and older.
* Ability to understand and willingness to sign a written consent document.
* Patients that received cisplatin in combination with other chemotherapeutic agents are eligible.
* Patients that received cisplatin in the context of a clinical trial are eligible.

Exclusion Criteria:

* Unable or unwilling to submit to a one-time blood draw.
The Effect of Acupressure on Pain, Nausea-Vomiting, and Mental Well-Being in Oncology Patients

The goal of this clinical trial is to compare the effect of self acupressure and acupressure applied by therapists on pain, nausea-vomiting, and mental well-being in oncology patients.

For this purpose, 93 individuals with stage 1-stage 3 cancer will be included in the study.

The main questions it aims to answer are:

• Is acupressure effective on pain, nausea-vomiting and mental well-being in oncology patients? Is there a difference in the effectiveness of self-acupressure and acupressure applied by therapist on pain, nausea-vomiting and mental well-being? The participants will be included in the study as three groups, namely the self-acupressure group, the acupressure group applied by the therapist, and the control group.

Self-acupressure participants will self-administer acupressure. In the acupressure group, which will be applied by the therapist, acupressure will be applied to the participants by researchers who have acupressure certificate.

In the control group, acupressure etc. No additional application will be made. Visual analog scale, nausea-vomiting and retching index, and mental well-being scales will be applied to all groups at the beginning of the study and three days after the study.

Large Intestine Meridian 4th point (Hegu/LI4), Pericardium Meridian/Neiguan (P6) point and Yintang (EX-HN 3) point will be used for acupressure application in the research.

Eligibility Criteria:
Inclusion Criteria:

* ≥18 years
* Cancer patients without distant metastases in stage-1, stage-2 and stage-3 who have received at least one course of chemotherapy
* Pain degree 4 and above (will be evaluated with a visual analog scale)
* Nausea-vomiting degree of 4 and above (will be evaluated with a visual analog scale)
* Receiving standard antiemetic and standard analgesic treatment (All patients included in the study should receive similar treatment.)
* No previous acupressure experience
* Absence of any wound or lesion in the area where acupressure will be applied.
* Not using a different complementary approach during the collection of research data
* Those who signed the Informed Consent Form/Written Consent Form
* Patients without any psychiatric diagnosis will be included in the study.

Exclusion Criteria:

* \< 18 years old
* Those who have not received chemotherapy before
* Pain grade below 4 (will be evaluated with a visual analog scale)
* Nausea-vomiting degree below 4 (will be evaluated with a visual analog scale)
* Receiving different antiemetic and analgesic treatments
* Previous acupressure experience
* Any wound or lesion in the area where acupressure will be applied
* Using a complementary approach other than acupressure at the time research data was collected
* Those who did not sign the Informed Consent Form/Written Consent Form
* Patients with any psychiatric diagnosis will not be included in the study.
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops

A randomized, double-blind, placebo-controlled, multicenter, phase III clinical study of the efficacy and safety of two low-concentration atropine sulfate eye drops in slowing the progression of myopia in children

Primary objective is to evaluate the efficacy and safety of atropine sulfate eye drops versus placebo for 12 months in slowing the progression of myopia in children.

The study was designed to enroll approximately 777 subjects. Eligible subjects were randomly assigned to the placebo control group, Lower dose atropine group and Lower dose atropine group. Subjects received the study medication in both eyes, 1 drop each time, once every night at bedtime.

Statistical analyses were performed with the use of SAS software, version 9.4, without any specific description. All statistical tests were two-sided at a 0.05 level.

Eligibility Criteria:
Inclusion Criteria:

1. Child (female or male) aged 6 to 12 years.
2. Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measuredby cycloplegic autorefraction.
3. If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction.
4. Anisometropia SER of \< 1.50 D as measured by cycloplegic autorefraction.

Exclusion Criteria:

1. Have used other myopia control methods other than those used in this study, such as instruments (orthokeratology lenses, multifocal glasses, progressive glasses), drugs (atropine, etc.); Only single vision glasses are allowed for myopia correction;
2. Have used myopic control methods such as traditional Chinese medicine, auricular acupuncture, massage, and reverse beat within 30 days before screening;
3. Use of any local or systemic antimuscarinic/anticholinergic medication (e.g., atropine, scopolamine, tropicamide, phenamine, diphenhydramine, oxytropine, tricyclic antidepressant, etc.) within 21 days before screening; Allowing for tests such as cycloplegic optometry;
Mixed Reality With Hololens® Exercise Protocol

The study design is a cross-over pilot study with 15 asymptomatic subjects. There will be 2 groups, mixed reality group and conventional cervical exercise program. Both groups received 2 sessions per week with an interval of 48 hours between them during 3 consecutive weeks.

The study design is a cross-over pilot study. The study was approved by the ethical committee of the Centro Superior de Estudios Universitarios La Salle. People were recruited by referral from different places of the local community of Madrid according to the CONSORT statement (Consolidated Standards of Reporting Trials). Three assessors were trained during 300 minutes about how to perform the measurements (Investigator A) and the concerned intervention to each group (Investigator B and C). The whole procedure was conducted in the Centro Superior de Estudios Universitarios La Salle. After meeting the eligibility criteria for the study, participants were randomly allocated by an external investigator to one of the two groups:

* Mixed reality group
* Conventional Exercise group

Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 40,
* Not experienced any neck and upper limb symptom
* Have no significant history of chronic pain disorder,
* Did not use any medication,
* Understand, write and speak Spanish fluently.

Exclusion Criteria:

* Craniocervical pain, peripheral neuropathy or history of migraine.
* Endocrine disorders, epilepsy or any psychiatric disorder, neurological disorder.
* Surgery and a history of traumatic injuries of the upper limb
Autologous Stem Cell Rescue for Primary Amyloidosis

To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

To learn about the use of high dose chemotherapy followed by transplantation using peripheral blood stem cells.

Eligibility Criteria:
Inclusion Criteria:1. Primary amyloidosis

2. Age \< 75 years.

3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

4. Patients who have undergone bone marrow transplantation previously will not be eligible.

5. Patients must have a Karnofsky performance status greater than 70%.

6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left ventricular ejection fraction \>45% on echocardiography, cardiac index \> 1.8 liters/min/m\^2 and pulmonary function tests demonstrating FEV1 and DLCO \> 60%.

7. Patients must be HIV negative.

8. Pregnant or lactating women will not be eligible to participate.

9. Patients must provide signed informed consent.

10. Patients with multiple myeloma and amyloid are eligible.

Exclusion Criteria:1. prior blood or marrow transplant
Awe Inducing Elements in Virtual Reality Applications: A Prospective Study of Hospitalized Children

This is an experimental study to evaluate which aspects of virtual reality (VR) software development can be optimized to increase awe in pediatric perioperative patients and their adult caregivers (e.g., parents, guardians)

Hospitalized pediatric patients, especially those undergoing anesthesia and surgery, experience anxiety and fear, resulting in lack of cooperation, withdrawal, and aggression. These reactions delay medical care and negatively impact patient experience.

This is an experimental, prospective study to evaluate which aspects of virtual reality (VR) software development can be optimized to increase awe in pediatric perioperative patients and their adult caregivers. The primary center for this study will be Lucile Packard Children's Hospital Stanford (LPCHS) (located within Stanford University, Palo Alto, CA).

After software development, we will evaluate the awe and engagement of pediatric patients after experiencing the novel virtual reality application.

Eligibility Criteria:
Inclusion Criteria:

* Patient with age range from 6 to 25
* Adult or LAR with age range from 18 to 99
* Able to consent or have parental consent
* in pre-operative holding and inpatient acute care areas of LCPH
* English speaking participants

Exclusion Criteria:

* People who do not consent
* Significant Cognitive Impairment
* History of Severe Motion Sickness
* Visual Problems
* currently have nausea
* history of seizures
* non-english participants
Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning

Ex vivo lung perfusion (EVLP) is not a new concept and has been widely used to study lung function in small animals. It also has been shown to be a useful technique to evaluate lungs from donation after cardiac death (DCD) (Yeung, Thorac Surg Clin, 2009). It has been recently demonstrated successful application of an acellular EVLP technique in optimalizing lung function ex vivo for an extended period of time. Following 12 h of normothermic EVLP, patients were transplanted and demonstrated immediate life-sustaining function with promising short-term evolution (Aigner, Am J Transplant, 2012; Sanchez, J Heart Lung Transplant, 2012; Cypel, N Engl J Med, 2011).

Lung donation obtained after carbon monoxide intoxication has been recognized as excellent organs because of less general inflammation and less primary graft dysfunction after procedure. In a murine model of brain dead, carbon monoxide inhalation at a low concentration (50 to 500 parts per million (ppm)) exerts significant cytoprotection in several lung injury models via its vasodilatation, anti-inflammatory, and anti-apoptotic properties (Dong, J Heart Lung transplant, 2010). The carbon monoxide inhalation down-regulates pro-inflammatory cytokines (TNF-alpha, IL-6) along with the increase of anti-inflammatory cytokine (IL-10) in recipient serum. The inhalation significantly decreases cell apoptosis in lung grafts, inhibiting mRNA and protein expression of intercellular adhesion molecule-1 (ICAM-1) and caspase-3 in lung grafts (Zhou, Chin Med J, 2008).

Apoptotis and inflammatory processes may, in part, concern alveolar tissue. Research in the field of biomarkers is now opening new perspectives with the development of non-invasive tests allowing for monitoring inflammation and damage in the deep lung. Blood tests (Bernard, Toxicol Appl Pharmacol, 2005) measuring lung-specific proteins (pneumoproteins) such as Clara cell protein (CC16) and surfactant-associated proteins (A, B or D) are now available to evaluate the permeability and/or the cellular integrity of the pulmonary epithelium. These dosages may constitute an interesting way for monitoring the quality of the lung before implantation.


Eligibility Criteria:
Inclusion Criteria:

Lung Edema

Exclusion Criteria:

Infection Severe Emphysema Tumor
Effects of Different I:E Ratio on Intrapulmonary Shunt Fraction and Oxygenation During One Lung Ventilation in the Lateral Decubitus Position

The purpose of this study is to investigate effect of increasing inspiratory time (I:E ratio 1:1) on intrapulmonary shunt fraction and oxygenation during one lung ventilation in the lateral decubitus position.

Increasing inspiratory time(e.g. Inverse ratio ventilation) has been known that had advantage of alveolar recruitment, preventing of ateletasis. On the contrary, it has disadvantange of intrinsic PEEP, air trapping. There is few study on one lung ventilation in lateral decubitus position about this ventilation method. We were going to investigate effecf of this ventilation method.

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status class I, II
* Use of Double lumen tube
* Unilateral lung lobectomy

Exclusion Criteria:

* COPD
* CAOD
* Unstable hemodynamic status
* Peak airway pressure \> 30mmHg (Two lung ventilation)
What is the Optimal Cycle Regimen for Frozen- Thawed Embryo Transfer Cycles

Investigators will be comparing artificial (HRT) frozen-thawed embryo transfer cycles to correctly conducted spontaneous natural cycles after the transfer of a chromosomally normal embryo.

The most common treatment protocols for frozen embryo transfers include natural cycles with or without human chorionic gonadotrophin (HCG) trigger or endometrial preparation with hormonal treatment (artificial cycles), with or without Gonadotrophin - releasing hormone agonist suppression. Recent studies comparing artificial and natural cycles concluded that the optimal means of endometrial preparation for frozen- thawed cycle remains unclear and both options may be offered to women with regular ovulatory cycles.

Correctly identified spontaneous natural cycles are the preferred option for frozen-thawed embryo transfer in women with regular menstrual cycles.

Investigators will be comparing artificial (HRT) frozen-thawed embryo transfer cycles to correctly conducted spontaneous natural cycles after the transfer of a chromosomally normal embryo.

Eligibility Criteria:
Inclusion criteria include the following:

1. Women aged 18 years to 42 years with regular menses (26-34 days)
2. Having 1 or 2 chromosomally normal cryopreserved blastocysts available for transfer.
3. First frozen-thawed transfer cycle
4. Progesterone level \< 1.5 ng/mL day of trigger injection in stimulation cycle from which embryos to be transferred were created.

Exclusion criteria include the following:

1. Polycystic ovarian syndrome
2. Poor ovarian responder in accordance with Bologna criteria
3. Uterine abnormality US / saline infusion sonohysterogram
4. Previous dilatation \& curettage (D\&C)
5. Hydrosalpinx
6. Asherman syndrome
7. History of endometriosis
8. ICSI due to severe male factor with testicular sperm
9. Any known contraindications or allergy to oral estradiol or progesterone.
10. Discontinuation of HRT medication ( medication error in research HRT cycle )
11. Failure to detect ovulation in the research natural cycle
12. Duration of estradiol exposure ≥ 17 days and endometrium \< 6mm
13. Spontaneous ovulation in HRT artificial cycle